OLEO

Oleo Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for rare neurodegenerative diseases. The company's primary focus is on its proprietary platform of deuterated polyunsaturated fatty acids (D-PUFAs), which are designed to stabilize cellular membranes against lipid peroxidation. By replacing susceptible natural fats with these fortified versions, Oleo aims to halt the oxidative damage that drives the progression of devastating conditions like Friedreich's Ataxia and Infantile Neuroaxonal Dystrophy. Formed to advance assets previously held by Retrotope, the company is currently progressing its lead candidate, OLT-101, through late-stage clinical development. Oleo's approach represents a novel strategy in mitochondrial medicine, targeting the fundamental biochemical triggers of cell death in orphan diseases.